Noxopharm Limited (ASX:NOX) CEO & Founder Dr Graham Kelly provides a summary and latest updates for the DAART Program. University of Wollongong's Head of School & Dean of Medicine, Professor Paul de Souza analyses DAART-1 results and efficacy signals.
Agenda: - DARRT Program Summary
- Study conclusions
- Eligible patients
- DARRT-1 Trial Design
- DARRT-1 Results (Dr de Souza)
- Unmet Clinical Need
- Comparisons
- DARRT-2/DARRT-3
- Milestones Ahead
- Recent M&A Activity
For more information, view the presentation by CEO & Founder Dr Graham Kelly and Head of School & Dean of Medicine, Professor Paul de Souza.